FDA highlights new tech to monitor trials

The FDA is encouraging drug developers to turn to new technology to help them monitor clinical trial work without resorting to frequent site visits, according to a report in Outsourcing-Pharma. In a new set of proposed guidelines, regulators specifically cited electronic data capture and statistical assessments to help them monitor the quality of the studies they sponsor. But no company, regulators add, should call a halt to their on-site visits. Story

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.